A. Goy Et Al. , "IMPACT OF STABLE DISEASE OR BETTER RESPONSES TO LENALIDOMIDE ON SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: MCL-001 (EMERGE) AND MCL-002 (SPRINT) STUDIES," 21st Congress of the European-Hematology-Association , vol.101, Copenhagen, Denmark, pp.477, 2016
Goy, A. Et Al. 2016. IMPACT OF STABLE DISEASE OR BETTER RESPONSES TO LENALIDOMIDE ON SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: MCL-001 (EMERGE) AND MCL-002 (SPRINT) STUDIES. 21st Congress of the European-Hematology-Association , (Copenhagen, Denmark), 477.
Goy, A., Arcaini, L., Williams, M. E., Lamy, T., Besisik, S., Drach, J., ... Ramchandren, R.(2016). IMPACT OF STABLE DISEASE OR BETTER RESPONSES TO LENALIDOMIDE ON SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: MCL-001 (EMERGE) AND MCL-002 (SPRINT) STUDIES . 21st Congress of the European-Hematology-Association (pp.477). Copenhagen, Denmark
Goy, A. Et Al. "IMPACT OF STABLE DISEASE OR BETTER RESPONSES TO LENALIDOMIDE ON SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: MCL-001 (EMERGE) AND MCL-002 (SPRINT) STUDIES," 21st Congress of the European-Hematology-Association, Copenhagen, Denmark, 2016
Goy, A. Et Al. "IMPACT OF STABLE DISEASE OR BETTER RESPONSES TO LENALIDOMIDE ON SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: MCL-001 (EMERGE) AND MCL-002 (SPRINT) STUDIES." 21st Congress of the European-Hematology-Association , Copenhagen, Denmark, pp.477, 2016
Goy, A. Et Al. (2016) . "IMPACT OF STABLE DISEASE OR BETTER RESPONSES TO LENALIDOMIDE ON SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: MCL-001 (EMERGE) AND MCL-002 (SPRINT) STUDIES." 21st Congress of the European-Hematology-Association , Copenhagen, Denmark, p.477.
@conferencepaper{conferencepaper, author={A. Goy Et Al. }, title={IMPACT OF STABLE DISEASE OR BETTER RESPONSES TO LENALIDOMIDE ON SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: MCL-001 (EMERGE) AND MCL-002 (SPRINT) STUDIES}, congress name={21st Congress of the European-Hematology-Association}, city={Copenhagen}, country={Denmark}, year={2016}, pages={477} }